Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants

Value in Health

Volumn 4, Issue 5, 2001, Pages 362-369

  Poret, Amy W ^a   Neslusan, Cheryl ^a   Ricci, Jean François ^b   Wang, Shaohung ^a   Khan, Zeba M ^b   Kwong, Jacqueline W ^b  

^a MEDSTAT GROUP   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Antidepressants; Bupropion SR; Direct medical costs; Retrospective analysis

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; ARTICLE; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SUSTAINED RELEASE FORMULATION;

EID: 0034790037     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2001.45068.x     Document Type: Article

References (34)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States
2. The economic burden of depression in 1990
3. Novartis pharmacy benefit report. Facts & figures
4. Bupropion slow-release response in depression: Diagnosis and biochemistry
5. A multi-center evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients
6. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients
7. Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs
8. Bupropion sustained release: Side effect profile
9. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary
10. Evaluating the tolerability of the newer antidepressants
11. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine
12. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects
13. Comparisons of bupropion and trazodone for the treatment of major depression
14. Advances in the management of depression: Implications for the obstetrician/gynecologist
15. Contemporary management of depression
16. Controlling for systematic selection in retrospective analyses: An application to fluoxetine and sertraline prescribing in the United Kingdom
17. What does treatment of depression really cost?
18. Cost-effectiveness of antidepressant medication
19. Antidepressant selection and use and healthcare expenditures: An empirical approach
20. Comparing SSRI treatment costs for depression using retrospective claims data: The role of nonrandom selection and skewed data
21. SSRI antidepressant selection and anxiolytic and sedativehypnotic use
22. Psychiatric patient classification system: An alternative to diagnoses-related groups
23. Much ado about two: Reconsidering retransformation and the two-part model in health econometrics
24. Measuring what works in health care
25. A comparison of observational studies and randomized, controlled trials
26. Randomized, controlled trials, observational studies, and the hierarchy of research designs
27. The effect of initiating therapy on fluoxetine and dothiepin on health care resource utilization in the United Kingdom
28. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization
29. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: A multivariate analysis
30. Problems with currently available antidepressants
31. New directions in the treatment of antidepressant-induced sexual dysfunction
32. Antidepressant-induced sexual dysfunction: A multicenter and prospective study using a questionnaire of 693 patients